The development of antipsychotic drugs
| Autor: | David G. C. Owens, Eve C. Johnstone |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment extrapyramidal side-effects Disease Review Article 03 medical and health sciences 0302 clinical medicine Dopamine medicine Antipsychotics 030212 general & internal medicine Antipsychotic Psychiatry Dopamine hypothesis of schizophrenia Clozapine clozapine General Neuroscience atypical antipsychotics medicine.disease 030227 psychiatry Tolerability Drug development Schizophrenia Neurology (clinical) dopamine Psychology pharma investment medicine.drug |
| Zdroj: | Brain and Neuroscience Advances |
| ISSN: | 2398-2128 |
| Popis: | Antipsychotic drugs revolutionised psychiatric practice and provided a range of tools for exploring brain function in health and disease. Their development and introduction were largely empirical but based on long and honourable scientific credentials and remarkable powers of clinical observation. The class shares a common core action of attenuating central dopamine transmission, which underlies the major limitation to their use – high liability to disrupt extrapyramidal function – and also the most durable hypothesis of the basis of psychotic disorders, especially schizophrenia. However, the Dopamine Hypothesis, which has driven drug development for almost half a century, has become a straight-jacket, stifling innovation, resulting in a class of compounds that are largely derivative. Recent efforts only cemented this tendency as no clinical evidence supports the notion that newer compounds, modelled on clozapine, share that drug’s unique neurological tolerability and can be considered ‘atypical’. Patients and doctors alike must await a more profound understanding of central dopamine homeostasis and novel methods of maintaining it before they can again experience the intoxicating promise antipsychotics once held. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|